Quadrant Capital Group LLC increased its holdings in Genmab A/S (NASDAQ:GMAB – Free Report) by 16.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,274 shares of the company’s stock after buying an additional 1,030 shares during the period. Quadrant Capital Group LLC’s holdings in Genmab A/S were worth $276,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently bought and sold shares of the company. First Manhattan Co. bought a new position in Genmab A/S in the fourth quarter worth approximately $26,000. Parallel Advisors LLC raised its stake in Genmab A/S by 54.8% in the second quarter. Parallel Advisors LLC now owns 1,158 shares of the company’s stock worth $44,000 after buying an additional 410 shares in the last quarter. Great West Life Assurance Co. Can raised its stake in Genmab A/S by 69.0% in the first quarter. Great West Life Assurance Co. Can now owns 1,590 shares of the company’s stock worth $60,000 after buying an additional 649 shares in the last quarter. Captrust Financial Advisors increased its position in shares of Genmab A/S by 62.0% during the first quarter. Captrust Financial Advisors now owns 2,658 shares of the company’s stock worth $96,000 after purchasing an additional 1,017 shares in the last quarter. Finally, Atlas Capital Advisors LLC increased its position in shares of Genmab A/S by 176.4% during the fourth quarter. Atlas Capital Advisors LLC now owns 2,488 shares of the company’s stock worth $105,000 after purchasing an additional 1,588 shares in the last quarter. Institutional investors own 6.29% of the company’s stock.
Genmab A/S Stock Performance
NASDAQ:GMAB opened at $32.80 on Friday. Genmab A/S has a one year low of $27.74 and a one year high of $47.50. The firm has a market cap of $21.67 billion, a price-to-earnings ratio of 34.89, a PEG ratio of 2.11 and a beta of 1.00. The firm’s fifty day moving average is $32.95 and its two-hundred day moving average is $36.92.
Wall Street Analyst Weigh In
Genmab A/S Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
- Five stocks we like better than Genmab A/S
- The “How” and “Why” of Investing in 5G Stocks
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 11/13 – 11/17
- How to Calculate Options Profits
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.